Abstract
Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Current Molecular Pharmacology
Title:Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Volume: 5
Author(s): Ulf Krause and Carl A. Gregory
Affiliation:
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Abstract: Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Export Options
About this article
Cite this article as:
Krause Ulf and A. Gregory Carl, Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent, Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020164
DOI https://dx.doi.org/10.2174/1874467211205020164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Emerging Technologies for Fertility Preservation in Female Patients
Current Women`s Health Reviews Stress Relaxation Testing of Non-Small Lung Cancer Cells Using Atomic Force Microscopy
Current Nanoscience Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry β-Aryl-ς-Hydroxy-γ-Lactones: Synthesis, Structural Analysis and Cytotoxic Activity
Current Organic Synthesis The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders
Current Molecular Pharmacology Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Synthetic and Biological Aspects of Thiadiazoles and their Condensed Derivatives: An Overview
Current Topics in Medicinal Chemistry Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine